Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis

Cao, Lihong

doi:10.1186/s12957-018-1485-4

Cited by 19 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in line with those described in a US large investigation which have reported that CD, not UC, was associated with a high risk of thyroid cancer [20]. On the contrary, a recent meta-analysis reported that patients with UC had an increased risk of thyroid cancer, while patients with CD did not [23]. It is possible that the inflammatory response of IBD itself and the use of immunosuppressants may contribute to the development of thyroid cancer.…”

Section: Plos Onesupporting

confidence: 92%

Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy

et al. 2020

View full text Add to dashboard Cite

The cancer risk of patients with inflammatory bowel diseases (IBD) has not been well documented in southern Europe. This study aimed to evaluate the overall pattern of cancer risk among patients with IBD in Friuli Venezia Giulia, northeastern Italy. A population-based cohort study was performed through a record linkage between local healthcare databases and the cancer registry (1995-2013). We identified 3664 IBD patients aged 18-84 years, including 2358 with ulcerative colitis (UC) and 1306 with Crohn's disease (CD). Sex-and age-standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were used to compare the cancer incidence of IBD patients with the general population. The cumulative cancer risk among IBD patients reached about 10% after 10 years of follow-up. A total of 246 cancers occurred among UC patients (SIR = 1.05, 95% CI: 0.92-1.19), and 141 among CD patients (SIR = 1.20, 95% CI: 1.01-1.41). As compared with the general population, no increased risk of colorectal cancers was observed for either UC or CD patients, whereas the risk of anal cancer was significantly elevated among UC patients (SIR = 6.03, 95% CI: 1.24-17.60). Increased risks were seen for specific extra-intestinal cancers, including corpus uteri (SIR = 2.67, 95% CI: 1.07-5.50) and kidney (SIR = 2.06, 95% CI: 1.03-3.69) among UC patients; thyroid (SIR = 5.58, 95% CI: 2.41-11.00) and skin non-melanoma (SIR = 1.86, 95% CI: 1.32-2.55) among CD patients. This population-based study showed that both UC and CD patients had a colorectal cancer risk similar to that of the general population. However, they were at a higher risk of developing certain extra-intestinal cancer types. Although detection biases cannot be excluded, the study findings pointed to a role of long-standing exposures to immunosuppressive therapies, underlying disease status, as well as the interactions with lifestyle factors. Our findings lent additional support to the need for monitoring the cancer burden in this at-risk population.

show abstract

Section: Plos Onesupporting

confidence: 92%

Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The included meta-analyses were published in English between 2014 and 2019. Various disease outcomes included cancers (n=7) [26][27][28][29][30][31], cardiovascular and cerebrovascular diseases (n=8) [32][33][34][35], obstetrical diseases (n=4) [36], neuropsychiatric disease (n=1) [38], otolaryngology and stomatology diseases (n=2) [41,43] and others (n=6) [37,[39][40]42,44] (Table 1). A total of 249 individual study estimates were included among the 19 articles.…”

Section: Resultsmentioning

confidence: 99%

“…By stratifying based on the type of IBD, CD was signi cantly associated with an elevated risk of cervical cancer, while UC was not [27]. UC was increased the risk of thyroid cancer, while CD was not [29] (Fig. 3A-B).…”

Section: The Associations Between Ibd and Cancersmentioning

confidence: 99%

“…Moderate quality of evidence shows that there was positive associations between IBD and risk of thyroid cancer (OR=1.75; 95% CI, 1.48-2.07) (Table 2 and Supplemental Table 4) [29]. Low quality of evidence shows that IBD was associated with an increased risk of cervical cancer [27], intrahepatic cholangiocarcinoma [30], melanoma [31] and extrahepatic cholangiocarcinoma [30].…”

Section: The Associations Between Ibd and Cancersmentioning

confidence: 99%

“…By stratifying based on age, IBD was associated with a higher risk of colorectal cancer in patients of age 30 years, but not in the patients age ≥ 30 years (Supplemental Table 1) [28]. By stratifying based on study design, IBD was associated with an increased risk of thyroid cancer and melanoma in population-based studies, but not in hospital based studies [29,31] (Supplemental Table 2). By stratifying based on the number of patients, IBD was associated with an increased risk of thyroid cancer in the studies with ≥ 10,000 patients, but not in those with 10,000 patients [29].…”

Section: The Associations Between Ibd and Cancersmentioning

confidence: 99%

See 2 more Smart Citations

The Associations between Inflammatory Bowel Disease and a Range of Other Diseases：Umbrella Review of Systematic Reviews and Meta-analyses

Cen

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Multiple meta-analyses have reported inflammatory bowel diseases (IBD) are associated with an increased risk of diverse diseases, but the evidence quality remains unclear. Objectives We aimed to summarize and evaluate this existing evidence on the associations between IBD and a range of diseases a-crossed from meta-analyses. Methods PubMed, the Cochrane Library Database, Embase, Web of Science, CNKI Databases, Wanfang Databases and VIP Database were searched to obtain eligible literatures from inception to November 1, 2019. We appraised the methodological quality of the included meta-analyses using AMSTAR 2 tool, and evaluated the quality of evidence for each outcome using the GRADE approach. Results Nineteen articles covering associations between IBD and 28 types of health outcomes were included. The methodological quality of meta-analyses was rated moderate for 5.26%, low for 21.05%, and critically low for 73.68%. Overall, summary effect estimates were significant in 26 meta-analyses. The evidence quality was rated high for 3.57%, moderate for 21.43%, low for 28.57%, and very low for 46.43%. Evidence quality was high for association between IBD and an increased periodontitis risk (OR = 4.55; 95% CI, 3.00-6.19). Evidence quality was moderate for associations between IBD and an increased thyroid cancer risk (OR = 1.75; 95% CI, 1.48–2.07), myocardial infarction incidence (RR = 1.12; 95% CI, 1.05–1.21), preterm birth incidence (OR = 1.85; 95% CI, 1.67–2.05), stillbirth incidence (OR = 1.57; 95% CI, 1.03–2.38), gallstone disease prevalence (OR = 1.72; 95% CI, 1.40–2.12), and vitamin D deficiency prevalence (OR = 1.64; 95% CI, 1.30–2.08). Conclusions Though, associations between IBD and diverse diseases have been extensively studied, few of the reported associations have robust support. Further well-designed studies are essential to determine whether IBD increases the risk of other diseases.

show abstract

Impact of extrathyroidal autoimmune diseases on clinical features and the efficacy of Iodine‐131 therapy in patients with differentiated thyroid cancer

Long,

Li,

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveThe aim of this study is to assess the impact of extrathyroidal autoimmune diseases (ADs) on the clinical characteristics and efficacy of iodine‐131 (131I) therapy in patients with differentiated thyroid cancer (DTC).MethodsPatients with DTC who were received 131I therapy simultaneously were classified into the combination group (n = 35) and noncombination group (n = 146) depending on the presence of ADs. The clinical characteristics, such as gender, age, tumor lesions, lymph node metastasis, distant metastasis, 131I therapy efficacy, and use of levothyroxine, were compared between the two groups. Statistical analysis was conducted using SPSS 26.0 and R 4.0.3.ResultsThere was a statistically significant difference in age between the combination and noncombination groups (t = −2.872, p < .01), and the optimal cutoff value was 50.5 years. Propensity score matching was completed effectively on a total of 121 patients, using age as the matching factor, comprising 32 cases in the combination group and 80 cases in the noncombination group. The baseline demographic features of the two groups were equivalent after matching (p > .05), and there was no significant difference in the therapeutic efficacy of 131I between the two groups (p > .05). In the subgroup analysis involving patients aged great than 50.5 years, the levothyroxine/weight (µg/kg) was increased in the combination group, and the difference was statistically significant (p < .05).ConclusionWhile extrathyroidal ADs may enhance the detection of DTC among elderly women, they have no impact on the clinical characteristics of thyroid cancer or the efficacy of 131I therapy. ADs may necessitate higher per‐unit dosages of levothyroxine in patients with DTC, regardless of the clinical status. Consequently, it is not essential for nuclear medicine physicians to consider the presence of ADs when designing treatment plans for patients with DTC.

show abstract

Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis

Cited by 19 publications

References 34 publications

Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy

Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy

The Associations between Inflammatory Bowel Disease and a Range of Other Diseases：Umbrella Review of Systematic Reviews and Meta-analyses

Impact of extrathyroidal autoimmune diseases on clinical features and the efficacy of Iodine‐131 therapy in patients with differentiated thyroid cancer

Contact Info

Product

Resources

About